Protein phosphatase 2A (PP2A) is a serine/threonine-selective holoenzyme composed of a catalytic, scaffolding, and regulatory subunit. In the heart, PP2A activity is requisite for cardiac excitation-contraction coupling and central in adrenergic signaling. We found that mice deficient in the PP2A regulatory subunit B56a (1 of 13 regulatory subunits) had altered PP2A signaling in the heart that was associated with changes in cardiac physiology, suggesting that the B56a regulatory subunit had an autoinhibitory role that suppressed excess PP2A activity. The increase in PP2A activity in the mice with reduced B56a expression resulted in slower heart rates and increased heart rate variability, conduction defects, and increased sensitivity of heart rate to parasympathetic agonists. Increased PP2A activity in B56a +/− myocytes resulted in reduced Ca 2+ waves and sparks, which was associated with decreased phosphorylation (and thus decreased activation) of the ryanodine receptor RyR 2 , an ion channel on intracellular membranes that is involved in Ca 2+ regulation in cardiomyocytes. In line with an autoinhibitory role for B56a, in vivo expression of B56a in the absence of altered abundance of other PP2A subunits decreased basal phosphatase activity. Consequently, in vivo expression of B56a suppressed parasympathetic regulation of heart rate and increased RyR 2 phosphorylation in cardiomyocytes. These data show that an integral component of the PP2A holoenzyme has an important inhibitory role in controlling PP2A enzyme activity in the heart.
INTRODUCTION
Protein phosphorylation is tightly regulated through the coordinate activities of kinases and phosphatases. In response to acute stress or chronic disease, increased sympathetic input to the heart tunes cardiac automaticity and contractility through protein phosphorylation. Defects in phosphorylation cascades are directly linked to various cardiac pathologies including sinoatrial node disease, heart failure, and arrhythmia (1) (2) (3) . In heart failure, increased kinase activity is associated with defects in excitationcontraction coupling, arrhythmias, and metabolic depletion of the heart (2, 4). Clinically, suppression of kinase activity through the use of b-adrenergic receptor blockers in heart failure has remained a mainstay to mitigate morbidity and mortality (3, 5, 6) . However, protein kinases represent just one arm of the protein phosphorylation cascade. Kinase activity is countered by the enzymatic action of protein phosphatases that dephosphorylate the target substrates of kinases. The regulatory role of phosphatases in normal cardiac physiology and disease is poorly understood and has emerged as a critical element in regulating cardiac excitability and contractile function.
Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase that is ubiquitously distributed in many tissues, including the heart. Unlike many monomeric enzymes, PP2A is a holoenzyme composed of three subunits: the A structural subunits, the C catalytic subunits, and the B regulatory subunits. In vertebrates, PP2A structural and catalytic subunits are encoded by 2 genes, whereas regulatory subunits are encoded by 13 genes (7) . Because of their cell, tissue, and, presumably, target specificity, previous work in myocytes has illustrated that modulation of protein phosphatase subunits may represent a therapeutic avenue to treat aberrant cardiac electrical activity and arrhythmia (8) (9) (10) . Studies using global phosphatase inhibitors have suggested a role for PP2A and other phosphatases to tune the cardiac inotropic response (11) (12) (13) . In vitro work in myocytes has led to the proposal that microRNA (miR)-dependent reduction in the PP2A regulatory subunit B56a promotes arrhythmia susceptibility by suppressing dyadic PP2A activity, thus increasing the phosphorylation of the ryanodine receptor (RyR 2 ) and promoting diastolic Ca 2+ sparks, waves, and afterdepolarizations (14, 15) . Because inhibiting PP2A is a potential strategy for the prevention of common forms of arrhythmia associated with increased adrenergic activity, we tested the in vivo role of the B56a regulatory subunit in cardiac signaling and function.
Here, we found that cardiac PP2A-dependent phosphatase activity was directly regulated by the B56a subunit. Specifically, we identified B56a as an autoinhibitor of cardiac PP2A-dependent activity in vivo. B56a +/− and B56a −/− mice displayed an increase in PP2A-dependent phosphatase activity, and consistent with these data, we observe whole-animal, cellular, and molecular phenotypes directly linked with augmented PP2A. At the whole-animal level, mice with decreased B56a expression did not show changes in the abundance of other PP2A subunits and displayed decreased heart rate, heart rate variability, conduction defects, and increased sensitivity to parasympathetic agonists. At the myocyte level, reduced B56a expression was associated with reduced Ca 2+ waves and sparks in the presence of sympathetic stimulation. Finally, at the molecular level, B56a deficiency results in reduced phosphorylation of RyR 2 . In contrast, in vivo B56a overexpression, in the absence of changes in expression of other PP2A subunits, resulted in decreased phosphatase and parasympathetic activity associated with increased phosphorylation of RyR 2 . These data highlight the role of PP2A regulatory subunits for modulating cardiac signaling and function.
RESULTS
Mice with B56a deficiency do not display compensatory changes in the abundance of other PP2A subunits
To investigate the in vivo mechanisms for PP2A regulation in the heart, we engineered a mouse model with reduced B56a expression through a gene trap strategy, creating an early transcriptional termination sequence after the first exon of Ppp2r5a ( fig. S1, A and B) . Because our initial goal was to assess the effect of reduced B56a abundance (rather than complete B56a deficiency) on PP2A function and cardiac phenotypes, we first evaluated mice heterozygous for the null Ppp2r5a allele ( fig. S1 , A to C; B56a +/− mice). B56a +/− mice displayed~50% reduction of Ppp2r5a in the heart by quantitative real-time fluorescence polymerase chain reaction (qPCR) ( fig. S1D ). Moreover, B56a +/− mice displayed~40% reduction of B56a protein by immunoblot (fig. S1, E and F). The abundance of other regulatory subunits was not altered in B56a +/− heart. For example, the abundance of B56g, the most homologous B56 gene product, and PP2A catalytic and scaffolding subunits was similar in wild-type and B56a +/− hearts ( fig. S1 , E and G to I). PP2A activity is modified by methylation through leucine carboxymethyltransferase 1 (LCMT-1) and phosphatase methylesterase (PME-1) (7). The abundance of LCMT-1 and PME-1 was similar between genotypes ( fig. S1 , E, J, and K). Thus, the B56a +/− mouse provides an in vivo model to define the role of reduced B56a deficiency on PP2A regulation and cardiac physiology.
Reduced expression of B56a increases cardiac PP2A activity
The consequence of reduced PP2A regulatory subunit expression on PP2A activity is debated. Some in vitro studies suggest that B56a deficiency may reduce PP2A holoenzyme formation and subsequently decrease cellular PP2A activity (14, 15) . However, structural data support a model in which the PP2A scaffolding A and catalytic C subunits form a more active but less regulated enzyme in the absence of regulatory subunit association (16) . Further, there is evidence that simply increasing the ratio of catalytic (C) subunit to regulatory (B) subunit may be sufficient to increase PP2A activity (17) . To directly address this controversy, we assessed total and PP2A-specific phosphatase activity in B56a +/− mouse hearts. PP2A-specific activity was identified as the fostriecin-sensitive fraction of total phosphatase activity (14) . Although global phosphatase abundance did not differ between wild-type and B56a +/− hearts (Fig. 1A) , PP2A-dependent phosphatase activity was significantly increased in B56a +/− hearts (Fig. 1B) . In B56a
hearts, we observed increased PP2A (and total protein phosphatase) activity relative to either wild-type or B56a +/− hearts ( Fig. 1, A and B) . To test whether these findings were selective to the heart, we analyzed PP2A activity in cerebellar lysates of wild-type and B56a-deficient mice. Similar to the heart, PP2A activity was increased in the cerebellum of B56a-deficient mice compared with wild-type littermates (Fig. 1C) . These data identify an inhibitory role of the B56a subunit in phosphatase regulation, such that reduced B56a expression increases PP2A activity.
B56a
+/− and B56 −/− mice display cardiac phenotypes linked with increased PP2A activity Heart rate is tightly regulated by sympathetic and parasympathetic tone, and adrenergic imbalance is linked with sinus node disease (18) . We found that B56a +/− mice displayed bradycardia at baseline (Fig. 1 , D to G), heart rate variability compared with wild-type littermates (Fig. 1H) , and no significant difference in QT interval ( fig. S2 ). Similar to B56a +/− mice, B56a
−/− mice displayed bradycardia and heart rate variability compared with wildtype mice (Fig. 1, I to K). Because PP2A modulates cardiac signaling in response to increased sympathetic tone (8) , we examined cardiac function in B56a +/− mice after b-adrenergic receptor stimulation. Wild-type and B56a +/− mice showed similar peak heart rates in response to injection of isoproterenol (Fig.  1L) or strenuous exercise (fig. S3 ). However, in contrast to the rapid recovery of heart rate after isoproterenol treatment in wild-type mice, B56a +/− mice displayed a significant increase in the time for heart rate recovery (Fig. 1M) . Further, sympathetic stimulation accentuated heart rate variability and conduction phenotypes in B56a +/− mice. For example, B56a +/− mice regularly had second-degree atrioventricular block, characterized by continual PR interval prolongation followed by a dropped QRS signature ( fig. S4, A to D) . In addition, we observed sinus node pause or block indicated by the absence of P waves followed by a ventricular escape beat in B56a +/− mice, phenotypes associated with increased parasympathetic stimulation ( fig. S4 , A to D). B56a +/− or B56a −/− mice did not have ventricular arrhythmias after low-or high-dose isoproterenol treatment or in response to exercise-induced stress. In summary, mice with reduced B56a expression display sinus node and atrioventricular node arrhythmias consistent with increased PP2A activity and lack electrical phenotypes associated with ventricular arrhythmias at rest or after catecholamine stimulation.
B56a-deficient mice display aberrant muscarinic regulation
To further evaluate the role of increased PP2A function on cardiac function, we tested B56a +/− mice for increased sensitivity to parasympathetic agonists. The cholinergic agonist carbachol produced a transient decrease in heart rate followed by rapid recovery in wild-type mice. In contrast, B56a +/− mice had an increased parasympathetic heart rate response to carbachol and significantly prolonged recovery period (Fig. 1, N and O) . We observed similar findings in B56a −/− mice ( fig. S5 ). Electrocardiograms (ECGs) from wild-type mice showed an initial carbachol-dependent decrease in heart rate that rapidly returned to normal sinus rhythm (Fig. 1, N , respectively) (6, 19) . Our data demonstrated that B56a reduction resulted in increased PP2A activity that would be expected to decrease spark and Ca 2+ wave frequency. demonstrates the leftward shift to lower heart rates in B56a +/− mice when plotted as % of total incidences at defined heart rate intervals (bars represent all data points from n = 4 mice per genotype; *P < 0.05). (H) The average SD from each 5-s RR interval at the indicated heart rates, plotted to demonstrate the increased heart rate variability in B56a +/− compared to WT mice (n = 4 mice per genotype; *P < 0.05). (I) Quantification of mean heart rate for conscious WT and B56a −/− mice (n = 4 mice per genotype; *P < 0.05). (J) Heart rate distribution for WT and B56a −/− mice demonstrates a leftward shift to lower heart rates in B56a −/− mice when plotted as % of total incidences at defined heart rate intervals (bars represent all data points from n = 4 mice per genotype; *P < 0.05). (K) The average SD from each 5-s averaged RR interval at the indicated heart rates, plotted to demonstrate the increased heart rate variability in B56a −/− compared to WT mice (n = 4 mice per genotype; *P < 0.05). (L) WT and B56a +/− mice displayed similar peak heart rates after isoproterenol (Iso) injection (n = 3 mice per genotype; P = N.S.). (M) Heart rate recovery after isoproterenol injection was longer in B56a +/− mice than in WT mice (n = 3 mice per genotype; *P < 0.05). (N and O) After acetylcholine receptor activation with carbachol (CCH), B56a +/− mice had a more pronounced reduction in heart rate and increased period for heart rate recovery compared to WT mice (n = 3 mice per genotype; *P < 0.05 compared to WT).
Consistent with this hypothesis, spark frequency was reduced in B56a +/− myocytes (Fig. 2, A to E) . Moreover, Ca 2+ wave frequency after isoproterenol exposure was also significantly reduced in B56a +/− myocytes (Fig. 2F ) despite increased sarcoplasmic reticulum (SR) load and increased Ca 2+ transient amplitude (Fig. 2, G and H) . These data suggest a decrease in Ca 2+ sensitivity of the RyR 2 , typically associated with reduced phosphorylation of RyR 2 . Thus, B56a is required for normal SR Ca 2+ sparks and Ca 2+ waves, and reduced abundance of this protein decreases spark frequency and Ca 2+ waves.
B56a is critical for the regulation of atrial function and atrial myocyte calcium signaling PP2A-dependent regulation of RyR 2 activity is also critical for atrial function. Because B56a +/− mice showed defects in atrial function ( Fig. 1) , we tested the effect of reduced B56a expression on atrial function at both the level of the organism as well as the single atrial myocyte. Treatment with atropine plus propranolol [a validated protocol for combined autonomic blockade of sympathetic and parasympathetic signaling (20) ] revealed a mild yet significant reduction in the intrinsic heart rate of B56a-deficient mice ( fig. S8 ). Analysis of single isolated atrial myocytes revealed similar PP2A-based defects in Ca 2+ regulation as observed in ventricular myocytes, most notably decreased Ca 2+ wave phenotypes compared with wild-type atrial myocytes (Fig. 2,  I to N). Together, these data demonstrate that altered atrial function in mice with reduced B56a is associated with cardiacintrinsic effects and altered atrial myocyte Ca 2+ regulation.
B56a
+/− and B56a −/− hearts display reduced phosphorylation of RyR 2
As a first step to establish the cellular and molecular mechanisms for the B56a-dependent phenotypes, we examined the phosphorylation status of PP2A targets associated with excitation-contraction coupling. Consistent with increased PP2A activity and decreased Ca 2+ spark and wave frequency in B56a 
+/− hearts do not show changes in the phosphorylation status of select myofilament proteins PP2A has other targets in addition to the excitation-contraction coupling machinery in the heart, and its activity is tied to cardiac contractile function, metabolism, and with cardiac stress pathways likely unrelated to B56a (21, 22) . We therefore tested the impact of B56a reduction on the phosphorylation status of key myofilament proteins. The phosphorylation of myofilament PP2A target proteins including myosin, myosinbinding protein C, troponin T, tropomyosin, troponin I, and myosin light chain were not significantly different between wild-type and B56a +/− hearts ( fig. S12 ).
B56a +/− and B56a
−/− myocytes display increased perinuclear and nuclear PP2A localization B56a regulates the targeting of PP2A in myocytes (23) . We therefore examined the localization of PP2A core complex in B56a +/− and B56a −/− myocytes. As shown by our group and others, PP2A core enzyme subunits are distributed throughout the myocyte, in the cytosol, myofilaments, and nuclear envelope (fig. S13A) (7, 24) . However, in contrast to wild-type myocytes, localization of PP2A/A to the nuclear envelope and nucleus was increased in B56a +/− and B56a −/− myocytes ( fig. S13 , B and C). All PP2A/A localization was not dependent on B56a because we observed secondary cytosolic populations of PP2A/A in B56a −/− myocytes ( fig. S13C ). Defining additional pathways for PP2A core subunit targeting will be an important future area of research. These pathways may include other PP2A regulatory subunits as proposed by Rogers and colleagues (24) or by the direct association of PP2A core enzyme subunits with PP2A targets (5, 25).
B56a abundance is increased in mouse model of cardiac ankyrin-B deficiency
B56a is targeted to the cardiac dyad by association with the membrane adapter ankyrin-B (23). Loss of ankyrin-B in myocytes results in aberrant B56a targeting in myocytes, CaMKII-dependent hyperphosphorylation of RyR 2 , altered RyR 2 open probability, afterdepolarizations, and arrhythmia (23, 26, 27) . In patients harboring ANK2 loss-of-function variants, this mechanism underlies a form of potentially fatal catecholaminergic polymorphic ventricular arrhythmia (26, 27) . On the basis of our data, a major question was the basis for differential phenotypes observed between ankyrin-B +/− and B56a +/− mice. To address this question, we used an animal model of cardiac-selective ankyrin-B deficiency (aMHC-Cre; Ank2 f/f ; "ankyrin-B −/− mice"). These mice showed increased B56a abundance ( fig. S14) . Thus, mice with ankyrin-B and B56a deficiencies display distinct cellular phenotypes resulting in differential cardiac pathologies.
In vivo B56a expression augments cardiac sympathetic signaling
Reduced B56a expression results in increased cardiac PP2A activity and augmented parasympathetic function, supporting the role of B56a as an inhibitor of PP2A signaling. To explore this mechanism, we examined the in vivo sympathetic and parasympathetic balance of mice with increased B56a expression (B56a overexpression). B56a expression was targeted to the myocardium of wild-type mice by AAV9 [with internal ribosomal entry site (IRES) mCherry reporter]. The identical construct lacking the B56a complementary DNA (cDNA) (AAV9 mCherry alone) was used to control for the effect of viral transduction on cardiac function. Transgene expression was confirmed in the heart by mCherry expression in atrial and ventricular myocytes (Fig. 4, A and B) , and immunoblot of whole-heart lysates ( Fig. 4C) 4 weeks after expression. Transgene expression was equivalent between atria and ventricle (Fig. 4, B and D) . Consistent with the proposed role of B56a as an inhibitor of PP2A activity, PP2A-dependent phosphatase activity was decreased in B56a-transduced hearts compared with wild-type hearts (Fig. 4E) . Moreover, these mice showed altered cardiac physiology, including a higher resting heart rate ( Fig. 4F) , increased peak heart rate in response to either exercise or isoproterenol stimulation (Fig. 4G) , and altered responses to carbachol (Fig. 4, G to I) . Specifically, we observed a significantly blunted heart rate response to carbachol treatment (Fig. 4, G and H) . Further, expression of AAV9 B56a was sufficient to restore a normal heart rate response to carbachol in B56a +/− mice (Fig.  4, H and I) . Finally, consistent with reduced cardiac parasympathetic signaling, phosphorylation of RyR 2 at Ser 2808 and Ser 2814 was increased in wild-type mice transduced with AAV9 B56a compared with wild-type hearts (Fig. 4 , J and K) without changes in PP2A core subunit abundance. Together, our findings illustrated that expression of B56a (in the absence of altered abundance of PP2A catalytic and scaffolding subunits) was sufficient to alter cardiac parasympathetic signaling. 
DISCUSSION
Attempts to modulate PP2A function in vivo through altering either scaffolding or catalytic subunits results in mice with substantial phenotypes.
Overexpression of PP2A/C in mice results in cardiac dilation and hypertrophy, reduced L-type Ca 2+ current, and impaired contractility (17) . Similarly, overexpression of a dominant-negative PP2A/A subunit in mice that is unable to bind PP2A regulatory subunits causes dilated cardiomyopathy . (E) Relative PP2A activity in WT and B56a OE hearts (n = 4 hearts per genotype; *P < 0.05 compared to WT). (F) Conscious B56a-OE mice had higher resting heart rates than did WT mice (n = 3 mice per experimental group; *P < 0.05). (G) Conscious B56a OE mice had higher peak heart rates after isoproterenol injection than WT, B56a +/− , or control mCherrytransduced mice (n = 3 mice per experimental group; *P < 0.05). (H and I) Heart rates and heart rate recovery [t 1/2 (half-time)] of WT mice transduced with mCherry or mCherry B56a were compared to WT and B56a +/− mice (reported in Fig. 1 ) after injection of carbachol to activate acetylcholine receptors. B56a OE mice displayed a blunted heart rate response compared with WT, B56a +/− , and mCherry-transduced mice (n = 3 mice per experimental group; *P < 0.05). Heart rate recovery was more rapid in B56a OE mice than in WT mice, B56a +/− mice, or control mice transduced with AAV9 mCherry (n = 3 mice per experimental group; *P < 0.05). B56a expression in B56a +/− mice (gray symbols) restored carbachol heart rate response to levels similar to WT mice (n = 3 mice per experimental group; P = N.S. between WT and B56a +/− + B56a OE). (J and K) Representative immunoblots and quantification of WT and B56a OE mouse cardiac lysates illustrating increased phosphorylation of RyR 2 at Ser 2808 and Ser 2814 (n = 3 hearts per experimental group; *P < 0.05; phosphorylation was normalized to total RyR 2 ). The total abundance of RyR 2 , GAPDH, or PP2A/C did not differ between experimental groups (n = 3 hearts per experimental group; P = N.S.).
and decreased fractional shortening (28) . As an alternative approach, as well as to investigate the mechanisms underlying phosphatase regulation, we focused on the PP2A regulatory subunit family because of select subunit distribution patterns within cardiac chambers, cell types, and subcellular domains (7). For example, the regulatory subunit B56a is localized to transverse tubules by association with the adapter molecule ankyrin-B (23).
Modulation of B56a at these sites alters excitability in cultured cardiomyocytes (14) and has been linked with human arrhythmias associated with ankyrin-B dysfunction (29) . However, despite its potentially important role for modulation of electrical function, the in vivo role of B56a is unknown. Contrary to previous in vitro reports (14, 15) , in vivo B56a reduction did not promote phenotypes associated with ventricular arrhythmia. Our in vivo and myocyte findings demonstrate that chronic B56a reduction, in the absence of alterations in the abundance of PP2A catalytic and scaffolding subunits, increases PP2A-dependent phosphatase activity in the heart, thus reducing phenotypes linked with ventricular arrhythmia. In line with these findings, B56a
+/− mice displayed augmented parasympathetic regulation of heart rate and conduction defects. In contrast to previous publications manipulating B56a abundance in acutely isolated cardiomyocytes, in vivo cardiac B56a deficiency does not promote RyR 2 hyperphosphorylation, increased Ca 2+ spark and wave frequency, afterdepolarizations, and/or arrhythmia. Rather, we found that B56a +/− and B56a −/− atrial and ventricular myocytes showed reduced phosphorylation of RyR 2 at Ser 2808 and Ser
2814
, reduced Ca 2+ waves and sparks, and resistance to catecholamine and/or exercise stress-induced arrhythmias. We hypothesize that differences between this study and past work are likely rooted in the experimental model (in vivo animal model compared with acutely transfected or transduced myocytes) and approach (direct B56a regulation compared to miRdependent regulation with potentially multiple downstream targets).
Our data provide evidence that an integral component of the PP2A holoenzyme serves an autoinhibitory role to tune and/or temper increased PP2A enzyme activity in vivo. Although unexpected, our data illustrate the complexity of phosphatase signaling pathways in the heart. The PP2A B56a complex is tightly regulated by multiple pathways both basally and in disease states. On the basis of our current and past data (7, 26) , and the in vivo work of others using PP2A subunit overexpression models (17, 28) , we hypothesize that the PP2A B56a molecule serves multiple roles in regulating local PP2A function. First, on the basis of findings in humans and mice, B56a facilitates the targeting of the PP2A holoenzyme complex to the cardiac dyad to modulate RyR 2 phosphorylation (5). Second, because PP2A catalytic and scaffolding subunits may associate and display PP2A activity independent of regulatory subunit integration (28), we hypothesize that B56a may sequester and suppress free PP2A core enzyme that has higher activity than the holoenzyme (28) . Thus, in the B56a-deficient models, reduction of B56a regulatory subunit results in active, unregulated PP2A core enzyme activity, resulting in increased PP2A-dependent phosphatase activity, reduced RyR 2 phosphorylation, and reduced Ca 2+ wave and spark frequency. In contrast, in the ankyrin-B model ( fig. S14 ), we surmise that although B56a abundance was increased, global PP2A abundance was normal due to formation of the mature PP2A B56a holoenzyme. However, the holoenzyme might have been less efficiently localized to the cardiac dyad, resulting in increased phosphorylation of RyR 2 at Ser 2814 and increased arrhythmia burden. It is unexpected that 50% loss of a single regulatory subunit out of 13 could have such a substantial effect on cardiac function. However, these data demonstrate the key role of the B56a subunit as a nodal point for cardiac phosphatase activity in the regulation of cardiac signaling. Given the complexity of PP2A signaling in the heart, it will be interesting to compare potential differences in B56a regulation across cardiac pathologies, to define additional cardiac PP2A targets, and to test for susceptibility of heart failure and arrhythmia phenotypes in B56a-deficient and overexpression models in response to aging and/or stress (such as transaortic banding).
MATERIALS AND METHODS

Animal studies
All animal studies were performed in accordance with the American Physiological Society Guiding Principles for Research Involving Animals and Human Beings, and approved by Ohio State University Institutional Animal Care and Use Committee. The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.
B56a
+/− and B56a −/− mouse models B56a +/− and B56a −/− mice were created by inserting a gene trap vector, containing a premature stop codon, into the first intron of Ppp2r5a (mouse accession NM_144880) and backcrossed onto a pure C57BL6 background before the study. For verification of genotype, DNA was isolated and analyzed by PCR. B56a deficiency was further confirmed by reverse transcription PCR (RT-PCR) and immunoblot using B56a-specific primers and antibodies. B56a +/− and B56a −/− mice were born healthy in expected ratios. For all experiments in the manuscript, 8-to 10-week-old male and female mice were used for experiments. No gender-based differences in phenotypes were observed. Control experiments were performed using wild-type littermates from B56a +/− × B56a −/− crosses. For AAV9 transduction experiments, 4-week-old animals were injected with AAV9 and analyzed for phenotypes for 4 weeks.
ECG experiments
ECG recordings of ambulatory mice were collected by subcutaneously implanted radiotelemeters (Data Sciences International) as previously described (30) . Briefly, recordings were collected in conscious mice at baseline, post-isoproterenol (0.4 or 0.05 mg/kg), post-carbachol (0.1 mg/kg), and post-atropine (1.0 mg/kg). Data points shown consist of data from 5-s epochs (n = 3 to 5 mice per experimental condition).
Immunoblots and antibodies
Immunoblots of whole-ventricle tissue lysates were analyzed on Mini-PROTEAN Tetra Cell (Bio-Rad) on a 4 to 15% TGX precast gel (Bio-Rad) in tris/glycine/SDS buffer (Bio-Rad) as described (30) . Antibodies included the following: PP2A/A (Calbiochem 539509), PP2A-C subunit (1:500, Millipore 05-421), PPP2R5A (1:500, Abcam ab72028), PPP2R5C (1:500, Abcam ab94633), PME-1 (1-500, Abcam ab154569), LCMT-1 (1:500, OriGene clone 209), CaMKIId (1:1000, Santa Cruz Biotechnology SC-13082), PKA catalytic (1:2500, R&D Systems MAB5908), SERCA2 (1:2000, Pierce Antibodies IID8), PLB (1:10,000, Abcam ab2865), PLB Ser 16 (1:20,000, Badrilla A010-12), PLB Ser 17 (1:20,000, Badrilla A010-13) (31), RyR 2 (1:1000, Millipore), and GAPDH (1:5000, Fitzgerald). The polyclonal antiRyR 2 immunoglobulins directed against phosphorylated Ser 2808 (1:1000) or Ser 2814 (1:1000) have been previously described (32) . Secondary antibodies included donkey anti-mouse horseradish peroxidase (HRP) and donkey anti-rabbit HRP (Jackson Laboratories). Densitometry was performed using Adobe Photoshop software, and data were normalized to GAPDH or total RyR 2 or PLB present in each sample.
Confocal microscopy
Intracellular Ca
2+ handling, SR load, Ca 2+ sparks, and waves were assessed from isolated myocytes using the Ca 2+ -sensitive dye Fluo-4. Myocytes were paced at 1 and 4 Hz using field stimulation, and when indicated, cells were treated with 1 mM isoproterenol (33) . Immunostaining was performed as previously described (34) .
Statistics
Data are presented as means ± SEM. SigmaPlot 12.0 was used for statistical analysis. The Wilcoxon-Mann-Whitney U test was used to determine P values for single comparisons. One-way analysis of variance (ANOVA) was used for multiple comparisons with the Bonferroni test for post hoc testing. If the data distribution failed normality tests with the Shapiro-Wilk test, a Kruskal-Wallis one-way ANOVA on ranks was applied with a Dunn's multiple comparison test for significant P values. Categorical data were compared using c 2 test.
Cardiomyocyte preparations
Adult cardiomyocytes were prepared as previously described (35, 36) .
Real-time RT-PCR
Total RNA was isolated from the hearts of 8-week-old male mice using the Qiagen RNeasy Mini Kit following the manufacturer's instructions (Qiagen). RNA was treated with TURBO DNase (Invitrogen). First-strand cDNA was synthesized from 200 ng of RNA as a template using the SuperScript III First-Strand Synthesis System (Invitrogen). Real-time PCR was conducted on fast optical 96-well reaction plates using the StepOne Plus Real-Time PCR System (Invitrogen) in a 10-ml final volume, using 0. ]. C t values were normalized to wild-type samples to simplify data presentation.
Pro-Q Diamond staining
Tissue lysate was loaded on a 13% SDS-polyacrylamide gel electrophoresis gel and run for 45 min at 175 V, fixed overnight, and stained using the Pro-Q Diamond phosphoprotein basic staining protocol (Invitrogen). The gel was imaged in a Typhoon variable mode scanner (GE Healthcare) using an excitation wavelength of 532 and 610 nm 30 bandpass emission filter at a photomultiplier tube setting of 500. Gel was stained with SYPRO Ruby and imaged to determine total protein. Densitometric analysis was performed on each band, and the ratio of Pro-Q stain intensity to total protein intensity was calculated.
Protein phosphatase activity
Protein phosphatase activity was examined using the SensoLyte Protein Phosphatase Assay Kit (AnaSpec). Enzyme activity (nanomole per minute) was calculated using the following formula: (V × vol)/(e × l), where V is the reaction velocity [OD 405 (optical density at 405 nm) per minute], vol is the reaction volume in liters, e is the extinction coefficient of pNPP (1.78 × 10 4 M −1 cm −1
), and l is the path length of light through the sample in centimeters (for the 100 ml sample, l = 0.5 cm). Enzyme activity was normalized to protein concentration.
Assessment of recovery of heart rate after carbachol injection
The time to recovery to baseline heart after stimulation with carbachol was determined by fitting raw heart rate data to the best-fit curve using the modified Hill equation:
where HR max is heart rate at maximum recovery, t is time in seconds, t 1/2 is time to recovery of half HR max , and k is a constant that is equivalent to minimum heart rate in response to carbachol. Best-fit curves were assessed in GraphPad with no constraints applied to any variable.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/8/386/ra72/DC1 Fig. S1 . B56a +/− mice display reduced B56a abundance without changes in the abundance of PP2A core subunits. Fig. S2 . Wild-type and B56a +/− mice have similar QT intervals. Fig. S3 . Wild-type and B56a +/− mice have similar peak heart rates after exercise. 
